INB-300, a gamma-delta T cell chimeric antigen receptor (CAR) platform, demonstrated the ability to target cancer cells while sparing healthy…
IK-930 is a potent Hippo pathway inhibitor that selectively binds TEAD1 and broadly represses oncogenic TEAD signaling IK-930’s differentiated paralog…
BRISBANE, Calif., April 17, 2023 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics…
Creative Health Care Management (CHCM) Webinar May 12, 2023Bloomington, MN, April 17, 2023 (GLOBE NEWSWIRE) -- Zina Rodriguez, MSW, CDE…
– Preclinical data supports SENTI-202 as a potential first-in-class logic gated CAR-NK cell therapy; remains on track for IND submission…
New tissue imaging tool designed to revolutionize clinical researchSOUTH SAN FRANCISCO, Calif., April 17, 2023 (GLOBE NEWSWIRE) -- Standard BioTools…
BERKELEY HEIGHTS, N.J., April 17, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and…
Southlake, Texas, April 17, 2023 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”),…
Partner Gensco® Pharma preparing to commercially launch RIZAFILM® across the United States as soon as is practicableSAINT LAURENT, Quebec, April…
WARSAW, Ind., April 17, 2023 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (NASDAQ: KIDS), a company focused exclusively…